Corporate Communications | Sutro Biopharma, Inc.

“Unnatural Selection”

“Unnatural Selection” BioCentury, The Bernstein Report on BioBusiness January 10, 2011 issue article, “Unnatural Selection” in the Tools & Techniques section by BioCentury Senior Editor, Ms. Susan Schaeffer. Read...

Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics. Company’s First Major Collaboration Validates Potential of Biochemical Protein Synthesis Technology Platform.

Press Releases

Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics. Company’s First Major Collaboration Validates Potential of Biochemical Protein Synthesis Technology Platform. San Francisco, CA...

Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer Appointment Reflects Biopharmaceutical Company’s Commitment to the Development of Novel and Biosuperior Protein Therapeutics

Press Releases

Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer Appointment Reflects Biopharmaceutical Company’s Commitment to the Development of Novel and Biosuperior Protein Therapeutics San Francisco, CA Dec. 8, 2010 – Sutro Biopharma, a...

A Robust, Rapid and Scalable Cell Free Expression System for the Production and Engineering of Fab Antibodies

Presentations

A Robust, Rapid and Scalable Cell Free Expression System for the Production and Engineering of Fab Antibodies Garces, Eudean et. al., A robust, rapid and scalable cell free expression system for the production and engineering of Fab antibodies. Presented at the IBC...

Sutro Biopharma Secures $36.5 Million in Series C Financing

Press Releases

Sutro Biopharma Secures $36.5 Million in Series C Financing South San Francisco, CA Nov. 17, 2010 – Sutro Biopharma today announced that the company has secured $36.5 million in Series C financing. This financing will support the company’s ongoing...

« Older Entries

Next Entries »